Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.7M
2M shares
52-week range
$1.95 – $12.03
4% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
www.aclarion.comNo one on the platform currently holds ACON.
No tracked institution reports a position in ACON as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-03-28 | 1-for-27reverse |
| 2025-01-30 | 1-for-335reverse |
| 2024-01-04 | 1-for-16reverse |
No one on the platform has traded ACON yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ACON all these low floaters china scams popping they should come here and pump this US stock
View on StockTwits ↗$ACON it would be great if this shit went to $4 range before clarity trial news cuz then I am sure $8 to $12 would come
View on StockTwits ↗$ACON has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology. https://biotuesdays.com/2026/08/04/first-site-in-indiana-offers-aclarions-nociscan-for-lower-back-pain/
View on StockTwits ↗$ACON can we start a true reversal from here to clarity trial news! Come on!
View on StockTwits ↗$ACON we are green on a Friday hmm interesting. Could it be that these fucks started buying back? I mean they could buy half the float at this price lol
View on StockTwits ↗$ACON You guys are showing signs of life here....
View on StockTwits ↗$ACON Somebody pitch me here..why should I dump 20k in here for 10 thousand shares. - There is the low float which mostly consist of warrants and shares at 5.18 - There is the offer that they turned down for 4 per share. Which makes sense because they would sell the company at 10m while having 16m in cash - there is the 2.5m dollar worth of share buy back. Thinking like scam management here now --- I would buy in but not at this price. If I was them I would ride this 15 days into delisting.... Bring it down to it's knees and than buy up 3/4 of the float. ... Any other thoughts ? Ideas other than it's scam, bs, they belong in jail. Yes we know that. They all belong in jail.
View on StockTwits ↗$ACON with the cash position this stock should be trading at the $5.00 and above level but no one seems to trust the managment!!!!
View on StockTwits ↗$ACON jail this management and out the cash in the hands of credible honest management Tharmann is a criminal
View on StockTwits ↗$ACON I still own and did not expect $CERO to be De-listed last year for allowing shareholder equity to drop below $2.5 million and their numerous Reverse Splits. But, bam about $2 to less than $.10 in a day. Knowing J. Thramann and his friends that are running this company, I think the plan was always to sell the company (as Thramann has done before). Never to really have a viable revenue generating company. Remember, they just recently turned down a $4 cash offer to buy it.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $140000 | +81.8% | $-4.51 | $-4.51–$-4.51 | — | 1 |
| 2027 | $260000 | +85.7% | $-5.37 | $-5.37–$-5.37 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ACONAclarion, Inc. | $2.40 | +3.45% | $1M | — |
| BFRGBullfrog AI Holdings, Inc. Common Stock | $0.59 | +1.90% | $11M | — |
| BNBXBNB Plus Corp. | $0.16 | +0.00% | $210492 | — |
| CANFCan-Fite BioPharma Ltd. | $3.40 | -1.16% | $4M | — |
| CMNDClearmind Medicine Inc. | $1.85 | +12.12% | $3M | — |
| ENSCEnsysce Biosciences, Inc. | $0.35 | -12.59% | $5M | — |
Source: Financial Modeling Prep · peers by sector/industry
| KZIAKazia Therapeutics Ltd ADR | $13.21 | +3.28% | $21M | — |